Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 Opinion of Skadden, Arps, Slate, Meagher & Flom LLP
- 10.9 Form of Indemnity Agreement by and Between Celularity and Its Directors and Officers
- 10.22 License Agreement, Dated August 15, 2017, by and Between Celgene Corporation and Anthrogenesis Corp
- 10.23 Agreement and Plan of Merger, Dated July 1, 2017, by and Among Celularity Inc., Clarity Acquisition Corp, Clarity Acquisition II LLC, Anthrogenesis Corporation and Celgene Corporation
- 10.24 Contingent Value Rights Agreement, Dated August 15, 2017, by and Between Celularity Inc. and the Holders Named Therein, As Amended by Amendment No. 1 to the Contingent Value Rights Agreement, Dated March 4, 2021
- 10.25 Investment Rights Agreement, Dated August 15, 2017, by and Between Celularity Inc. and Celgene Corporation As Amended by Amendment No. 1 to the Investment Rights Agreement, Dated March 4, 2021
- 10.26 License and Transfer Agreement, Dated September 30, 2020, by and Between Celularity Inc. and Sorrento Therapeutics, Inc., As Amended
- 10.27 Agreement and Plan of Merger, Dated August 22, 2018, by and Among Celularity Inc., Caricord Inc, CC Subsidiary, Inc. and Gregory L. Andrews
- 10.34 Stock Purchase Agreement, by and Between Celularity Inc. and DR. Andrew C. Von Eschenbach, Dated As of September 18, 2020
- 23.1 Consent of Independent Registered Public Accounting Firm of GX Acquisition Corp
- 23.2 Consent of Independent Registered Public Accounting Firm of Celularity Inc.
- 99.1 Form of Preliminary Proxy Card
Associated filings
- 28 Jun 21 EFFECT Notice of effectiveness
- 25 Jun 21 424B3 Prospectus supplement
- 22 Jun 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 7 Jun 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 23 Apr 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
29 Mar 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 25 Jan 21 S-4 Registration of securities issued in business combination transactions
CELU similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement No. 333-252402 on Form S-4 of our report dated March 29, 2021, relating to the financial statements of Celularity Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
Parsippany, NJ
March 29, 2021